Improving Protocol Design Feasibility to Drive Drug Development Economics and Performance

Kenneth Getz
Additional contact information
Kenneth Getz: Center for the Study of Drug Development, School of Medicine, Tufts University, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA

IJERPH, 2014, vol. 11, issue 5, 1-12

Abstract: Protocol design complexity has increased substantially during the past decade and this in turn has adversely impacted drug development economics and performance. This article reviews the results of two major Tufts Center for the Study of Drug Development studies quantifying the direct cost of conducting less essential and unnecessary protocol procedures and of implementing amendments to protocol designs. Indirect costs including personnel time, work load and cycle time delays associated with complex protocol designs are also discussed. The author concludes with an overview of steps that research sponsors are taking to improve protocol design feasibility.

Keywords: protocol design complexity; protocol amendments; extraneous protocol procedures; direct drug development costs; indirect drug development costs; protocol feasibility (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/11/5/5069/pdf (application/pdf)
https://www.mdpi.com/1660-4601/11/5/5069/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:11:y:2014:i:5:p:5069-5080:d:35967

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().